 |
Photo = Yonhap news |
[Alpha Biz= Reporter Kim Jisun] Hanmi Science stated on the 4th that there is no issue with CEO Lim Jong-hoon exercising shareholder rights at Hanmi Pharm’s extraordinary general meeting scheduled for the 19th.
The company emphasized that there are no provisions in any laws, articles of association, or board regulations that restrict the CEO’s exercise of shareholder rights. As the extraordinary shareholders meeting was convened after thorough discussions by the board, there are no legal or procedural flaws.
Hanmi Science had already discussed the need for a change of directors at Hanmi Pharm and whether to withdraw the request for the extraordinary meeting at the board level on October 23, at the request of Director Song Yeong-sook.
The board of directors at that time voted against all of Song’s claims regarding the removal of directors and withdrawal of the meeting request, following proper procedures. Hanmi Science views the subsequent application for an injunction in court as an unreasonable and illogical act intended to provoke unnecessary conflict.
Hanmi Science further pointed out that Hanmi Pharm CEO Park Jae-hyun is under investigation for charges including breach of trust, embezzlement, and insider trading. Since August, Park's leadership under the guise of independent management has caused significant operational confusion and financial damage across the group. The company argued that Park should be dismissed at the upcoming extraordinary meeting due to his involvement in chaotic and secretive management actions driven by certain major shareholders.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
